SCYNEXIS INC (SCYX) Stock Price, Quote, News and Overview

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 29 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Company Info

SCYNEXIS INC

1 Evertrust Plaza, 13th Floor

Jersey City NEW JERSEY 07302 US

CEO: Marco Taglietti

Employees: 29

Company Website: https://www.scynexis.com/

Investor Relations: http://ir.scynexis.com/index.cfm

Phone: 12018845485